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SCIENTIFIC OPINION 
Scientific Opinion on application (EFSA-GMO-DE-2011-95) for the placing 
on the market of genetically modified maize 5307 for food and feed uses, 
import and processing under Regulation (EC) No 1829/2003 from Syngenta 
Crop Protection AG1 
EFSA Panel on Genetically Modified Organisms (GMO)2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Maize 5307 was developed by Agrobacterium tumefaciens-mediated transformation to express two proteins: 
eCry3.1Ab, conferring resistance to certain coleopteran pests, and phosphomannose isomerase (PMI), used as 
selection marker. The molecular characterisation showed relevant similarities between the amino acid sequence 
of PMI and a known allergen, and between the amino acid sequence of eCry3.1Ab and a potential toxin. Some 
agronomic and phenotypic differences between maize 5307 and its conventional counterpart were observed 
(higher ‘heat units to 50 % pollen shed’, grain moisture, plant height, grain yield); however, the EFSA GMO 
Panel considered that these do not give rise to food/feed or environmental safety concerns. No differences in the 
compositional data requiring further safety assessment were identified. There were no concerns regarding the 
potential toxicity and allergenicity of the PMI protein. The EFSA GMO Panel could not conclude on the safety 
of the eCry3.1Ab protein due to the inadequate 28-day toxicity study provided. The outcome of a broiler feeding 
study with maize 5307 was not assessed by the EFSA GMO Panel, due to study weaknesses. There are no 
indications of an increased likelihood of the establishment and spread of feral maize plants. Interactions with the 
biotic and abiotic environment were not considered to be a relevant issue. Risks associated with the unlikely but 
theoretically possible horizontal gene transfer of recombinant genes from maize 5307 to bacteria were not 
identified. The post-market environmental monitoring plan and reporting intervals are in line with the scope of 
the application. In conclusion, in the absence of an appropriate assessment of eCry3.1Ab, the EFSA GMO Panel 
is not in a position to complete its food/feed risk assessment of maize 5307. However, the EFSA GMO Panel 
concludes that the maize 5307 is unlikely to have any adverse effect on the environment in the context of its 
scope. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following the submission of an application (EFSA-GMO-DE-2011-95) under Regulation (EC) No 
1829/2003 from Syngenta Crop Protection AG, the Panel on Genetically Modified Organisms of the 
European Food Safety Authority (EFSA GMO Panel) was asked to deliver a scientific opinion on the 
safety of genetically modified (GM) maize 5307 (Unique Identifier SYN-Ø53Ø7-1). The scope of 
application EFSA-GMO-DE-2011-95 is for import, processing, and food and feed uses of maize 5307 
within the European Union (EU), as for any non-GM maize, but excludes cultivation in the EU. 
The EFSA GMO Panel evaluated maize 5307 with reference to the scope and appropriate principles 
described in its guidelines for the risk assessment of GM plants and derived food and feed, the 
environmental risk assessment of GM plants and the post-market environmental monitoring of GM 
plants. The scientific evaluation of the risk assessment included molecular characterisation of the 
inserted DNA and analysis of the expression of the corresponding proteins. An evaluation of the 
comparative analyses of the compositional, agronomic and phenotypic characteristics was undertaken, 
and the safety of the newly expressed proteins and the whole food/feed was evaluated with respect to 
potential toxicity, allergenicity and nutritional wholesomeness. An evaluation of environmental 
impacts and the post-market environmental monitoring plan was also undertaken. 
Maize 5307 was developed by Agrobacterium tumefaciens-mediated transformation of the 
conventional maize line NP2222. It expresses the chimeric eCry3.1Ab protein (based on a modified 
Cry3A from Bacillus thuringiensis subsp. tenebrionis and the Cry1Ab from B. thuringiensis subsp. 
kurstaki strain HD-1), which confers resistance to certain coleopteran pests, and the phosphomannose 
isomerase (PMI) protein, which is used as a marker for the selection of transformants. The molecular 
characterisation data established that the genetically modified maize 5307 contains a single insertion 
consisting of two intact expression cassettes (ecry3.1Ab and pmi). No other parts of the plasmid used 
for transformation are present in maize 5307. Bioinformatic analyses revealed sequence identities 
greater than 35 % with allergens in putative translation products of open reading frames (ORFs) newly 
created by the genetic modification. The likelihood that these ORFs are both transcribed and translated 
in maize 5307 is negligible. Bioinformatic analyses revealed relevant similarities between the amino 
acid sequence of PMI and a known allergen, and between the amino acid sequence of eCry3.1Ab and 
a potential toxin. These were further assessed for their relevance for food and feed safety. The stability 
of the inserted DNA was confirmed over several generations and a Mendelian inheritance pattern was 
demonstrated. The levels of the eCry3.1Ab and PMI proteins in maize 5307 were obtained and 
reported adequately. 
Based on the agronomic and phenotypic characteristics of maize 5307 tested under field conditions, 
some differences were noted in maize 5307 compared with its conventional counterpart (i.e. higher 
‘heat units to 50 % pollen shed’, higher grain moisture and higher plant height in 2007 field trials; 
higher grain yield in 2008 field trials). The EFSA GMO Panel is of the opinion that these do not give 
rise to any food and feed or environmental safety concerns. No differences requiring further 
assessment with regard to safety by the EFSA GMO Panel were identified at analyses of 
compositional data of forage or grains obtained from maize 5307. 
No safety concerns were identified regarding the potential toxicity and allergenicity of the newly 
expressed protein PMI. The 28-day rat oral toxicity study on eCry3.1Ab, provided to support the 
safety assessment of this newly expressed protein, was not considered adequate by the EFSA GMO 
Panel (i.e. use of datasets from two separate experiments and low number of animals per gender per 
group). Therefore, the EFSA GMO Panel could not conclude on the safety of the eCry3.1Ab protein. 
The EFSA GMO Panel could not evaluate the outcome of a feeding study in broilers with maize 5307 
because of weaknesses in the study conduct and reporting. 
The application GMO-DE-2011-95 concerns food and feed uses and import and processing. Therefore, 
there is no requirement for scientific information on possible environmental effects associated with the 
cultivation of maize 5307. There are no indications of an increased likelihood of the establishment and 
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spread of feral maize plants. Considering the scope of application EFSA-GMO-DE-2011-95, 
interactions with the biotic and abiotic environment were not considered to be a relevant issue. The 
EFSA GMO Panel also concludes that, considering the scope of application EFSA-GMO-DE-2011-
95, the unlikely but theoretically possible horizontal gene transfer of recombinant genes from maize 
5307 to bacteria does not give rise to any environmental safety concern. The post-market 
environmental monitoring plan and reporting intervals are in line with the scope of application EFSA-
GMO-DE-2011-95. 
In delivering its scientific opinion, the EFSA GMO Panel took into account application EFSA-GMO-
DE-2011-95, additional information provided by the applicant, scientific comments submitted by the 
Member States and relevant scientific publications. In conclusion, the EFSA GMO Panel could not 
complete the food and feed safety assessment of maize 5307 due to the lack of an appropriate 
assessment of the eCry3.1Ab protein. However, the EFSA GMO Panel concludes that maize 5307 is 
unlikely to have any adverse effect on the environment in the context of the scope of application 
EFSA-GMO-DE-2011-95. 
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BACKGROUND 
On 7 April 2011, the European Food Safety Authority (EFSA) received from the German Competent 
Authority an application (Reference EFSA-GMO-DE-2011-95) for authorisation of GM maize 5307 
(Unique Identifier SYN-Ø53Ø7-1), submitted by Syngenta Crop Protection AG within the framework 
of Regulation (EC) No 1829/2003 on GM food and feed.4 
After receiving the application EFSA-GMO-DE-2011-95 and in accordance with Articles 5(2)(b) and 
17(2)(b) of the Regulation (EC) No 1829/2003, EFSA informed the Member States and the European 
Commission, and made the summary of the application publicly available on the EFSA website.5 
EFSA initiated a formal review of the application to check compliance with the requirements laid 
down in Articles 5(3) and 17(3) of the Regulation (EC) No 1829/2003. On 31 May 2011, EFSA 
received additional information requested under completeness check (13 May 2011). On 21 June 
2011, EFSA declared the application as valid in accordance with Articles 6(1) and 18(1) of Regulation 
(EC) No 1829/2003. 
EFSA made the valid application available to Member States and the European Commission, and 
consulted nominated risk assessment bodies of Member States, including national Competent 
Authorities within the meaning of Directive 2001/18/EC6 following the requirements of Articles 6(4) 
and 18(4) of Regulation (EC) No 1829/2003, to request their scientific opinion. Member States had 
three months after the date of receipt of the valid application (until 21 September 2011) to make their 
opinion known. 
The EFSA GMO Panel carried out an evaluation of the scientific risk assessment of maize 5307 for 
food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation 
(EC) No 1829/2003. The EFSA GMO Panel took into account the appropriate principles described in 
its guidelines for the risk assessment of GM plants and derived food and feed (EFSA, 2006a; EFSA 
GMO Panel, 2011a), the environmental risk assessment of GM plants (EFSA GMO Panel, 2010c) and 
on the post-market environmental monitoring of GM plants (EFSA GMO Panel, 2011b). Furthermore, 
the EFSA GMO Panel also took into consideration the scientific comments of Member States, the 
additional information provided by the applicant and the relevant scientific publications. 
On 13 September 2011, 14 October 2011, 25 June 2013, 27 May 2014, 09 September 2014, 29 
October 2014, 16 February 2015 and on 27 February 2015, the EFSA GMO Panel requested additional 
information from the applicant. The applicant provided the requested information on 03 October 2011, 
29 January 2013, 08 August 2013, 12 June 2014, 18 September 2014, 11 December 2014 and on 24 
March 2015, respectively. The applicant also spontaneously provided additional information on 28 
July 2014. After evaluation of the full data package, the EFSA GMO Panel finalised its risk 
assessment of maize 5307. 
In giving its scientific opinion on maize 5307 to the European Commission, Member States and the 
applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA 
has endeavoured to respect a time limit of six months from the acknowledgement of the valid 
application. As additional information was requested by the EFSA GMO Panel, the time limit of six 
months was extended accordingly, in line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) 
No 1829/2003. 
                                                     
4
 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. OJ L 268, 18.10.2003, p. 1–23. 
5
 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2011-00310  
6
 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001,  
p. 1–38. 
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According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report 
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall 
opinion in accordance with Articles 6(5) and 18(5). 
TERMS OF REFERENCE 
The EFSA GMO Panel was requested to carry out a scientific assessment of maize 5307 for food and 
feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 
1829/2003. 
Where applicable, any conditions or restrictions which should be imposed on the placing on the 
market and/or specific conditions or restrictions for use and handling, including post-market 
monitoring requirements based on the outcome of the risk assessment and, in the case of GMOs or 
food/feed containing or consisting of GMOs, conditions for the protection of particular 
ecosystems/environment and/or geographical areas should be indicated in accordance with Articles 
6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003. 
The EFSA GMO Panel was not requested to give an opinion on information required under Annex II 
to the Cartagena Protocol. Furthermore, the EFSA GMO Panel did not consider proposals for labelling 
and methods of detection (including sampling and the identification of the specific transformation 
event in the food/feed and/or food/feed produced from it), which are matters related to risk 
management. 
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ASSESSMENT 
1. Introduction 
The genetically modified (GM) maize 5307 (Unique Identifier SYN-Ø53Ø7-1) was assessed with 
respect to the scope of application EFSA-GMO-DE-2011-95, taking into account the appropriate 
principles described in the applicable guidance documents (EFSA, 2006a, b; EFSA GMO Panel, 
2010c); and, whenever possible, also the current guidance documents (EFSA GMO Panel, 2011a, b). 
The risk assessment presented here is based on the information provided in the application relating to 
maize 5307 submitted in the EU, scientific comments raised by the Member States and relevant 
scientific publications. 
Maize 5307 expresses a chimeric Cry protein, designated eCry3.1Ab, which is based on a modified 
Cry3A protein (mCry3A) derived from Bacillus thuringiensis subsp. tenebrionis and the Cry1Ab from 
B. thuringiensis subsp. kurstaki strain HD-1. The protein confers resistance to certain coleopteran 
pests. The expression of the phosphomannose isomerase (PMI) protein is used as a marker for the 
selection of transformants. 
The genetic modification in maize 5307 is intended to improve agronomic performance only and is not 
intended to influence the nutritional properties, the processing characteristics or the overall use of 
maize as a crop. 
The scope of application EFSA-GMO-DE-2011-95 is for import, processing, and food and feed uses 
of maize 5307 and does not include cultivation in the European Union (EU). Thus, maize 5307 will be 
imported into the EU for food or feed uses in the same way as any commercial maize variety. Possible 
food and feed products include starch, syrup, ethanol, maize oil, flakes, coarse and regular grits, coarse 
and dusted meal, flour, maize germ meal, maize gluten and maize gluten meal. 
2. Issues raised by the Member States 
The comments raised by Member States are addressed in Annex G of the European Food Safety 
Authority (EFSA) overall opinion7 and were taken into consideration during the evaluation of the risk 
assessment. 
3. Molecular characterisation 
3.1. Evaluation of relevant scientific data 
3.1.1. Transformation process and vector constructs 
Immature embryos of a proprietary maize (Zea mays L.) line, NP2222, were transformed with the 
plasmid vector pSYN12274 using Agrobacterium tumefaciens (also known as Rhizobium radiobacter) 
strain LBA4404. The regeneration of the transformed tissue was achieved after a callus phase.8 
The plasmid pSYN12274 includes one T-DNA that contains the ecry3.1Ab gene expression cassette, 
providing expression of modified eCry3.1Ab protein, and the pmi gene expression cassette, providing 
expression of a PMI protein.9 
The T-DNA present in plasmid pSYN12274 contains the following elements between its respective 
right and left border region: 
• ecry3.1Ab gene expression cassette consisting of the CMP promoter from Cestrum Yellow Leaf 
Curling Virus; coding sequence for the engineered eCry3.1Ab protein; terminator sequence from 
                                                     
7 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2011-00310 
8
 Dossier: Part I—Section C1. 
9
 Dossier: Part I—Sections C2, C3, D1. 
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the nopaline synthase (nos) gene from A. tumefaciens, providing a polyadenylation signal. The 
ecry3.1Ab gene is based on the cry1Ab and the modified cry3A (mcry3A) genes derived from B. 
thuringiensis and consists of a fusion between the 5′ end of the mcry3A domain (459 amino acids) 
and the 3′ end of the cry1Ab domain (172 amino acids). Upstream of the mcry3A domain, a 67-bp 
oligomer extension was introduced during the engineering process and is translated into 22 amino 
acid residues at the N terminus of the chimeric eCry3.1Ab.10 
• pmi gene expression cassette consisting of the promoter and first intron from the maize 
polyubiquitin gene (ZmUbiInt); pmi gene from Escherichia coli encoding PMI, allowing selection 
of transformants using mannose as the sole carbon source; terminator sequence from the nopaline 
synthase (nos) gene from A. tumefaciens, providing a polyadenylation signal. 
Additional functional elements in the plasmid vector positioned outside the T-DNA (and not expected 
to be transferred into the maize genome), were: oriVS1 and repA, the origin of replication and 
replicase genes, respectively, both derived from the Pseudomonas aeruginosa plasmid pVS1 and 
required for the maintenance of the plasmid vector in Agrobacterium; virG, regulator of virulence in 
A. tumefaciens; oriColE1, the origin of replication required for the maintenance of pSYN12274 in E. 
coli; aadA from E. coli transposon Tn7, coding for a streptomycin adenyltransferase enzyme 
conferring resistance to spectinomycin and streptomycin for selection of the plasmid in E. coli and 
Agrobacterium. 
3.1.2. Transgene constructs in the genetically modified plant11 
The DNA sequences inserted in maize 5307 were characterised by Southern blot analysis, polymerase 
chain reaction (PCR) and sequencing of both the insert and flanking regions. 
Southern analysis indicated that maize 5307 contains a single insert with one copy of the intact 
ecry3.1Ab and pmi expression cassettes. The insert and copy number were confirmed by multiple 
restriction enzyme/probe combinations covering the T-DNA region and the flanking regions. No 
signal was observed, with the probe corresponding to the pSYN12274 vector backbone. 
The nucleotide sequences of the entire insert, as well as 1 kb of both 5′ and 3′ flanking regions were 
determined from maize 5307. The sequence of the insert confirmed the conclusions drawn from the 
Southern analyses. Comparison with the sequence of pSYN12274 indicated that the insert in maize 
5307 contained a single nucleotide difference 48 bp upstream of the CMP promoter. Furthermore, the 
entire right border including 3 bp of non-coding sequence at the 5′ end of the insert and 8 bp of the left 
border, were absent. None of the differences influenced the functionality of the insert. The possible 
interruption of known endogenous maize genes by the insertion in maize 5307, was evaluated by 
bioinformatic analyses of the pre-insertion locus and the genomic sequences flanking the insert. 
Comparison of the sequences of the flanking regions in maize 5307 with the conventional maize 
genomic sequences indicated a 33-bp deletion of maize DNA at the insertion site. BLASTN searches 
were performed against a plant EST (Expressed Sequence Tag) database and a non-redundant 
nucleotide database and BLASTX searches against a non-redundant amino acid database. These 
bioinformatic analyses did not reveal the interruption of any known endogenous gene in the maize 
5307 flanking regions.12  BLASTN analysis of the flanking sequences did reveal alignments with 
multiple maize BAC clones and suggested that the insert is located in a repetitive region of the maize 
genome. 
The results of segregation (see Section 3.1.4.) and bioinformatic analyses established that the insert is 
located in the nuclear genome.13 
                                                     
10
 Dossier: Part I—Section C3. 
11
 Dossier: Part I—Section D2. 
12
 Dossier: Part I —Section D2.4; additional information: 12/06/2014, 28/07/2014 and 24/03/2015. 
13
 Dossier: Part I —Sections D2.4, D5; additional information: 12/06/2014 and 28/07/2014. 
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In order to assess whether the open reading frames (ORFs) present within the insert and spanning the 
junction sites give rise to any safety issues, their putative translation products were compared with 
databases for similarities to known allergens and toxins relevant for humans and/or animals using 
suitable algorithms. By using an 80-amino-acid sliding window approach, a sequence identity greater 
than 35 % between putative translated products of five ORFs and known allergens were found by the 
applicant. Three ORFs are not in the codon frame intended to be expressed, do not include an ATG 
start codon and do not have known promoters in close proximity. Another ORF is not in the codon 
frame intended to be expressed and does not include an ATG start codon. Although the fifth ORF is in 
the codon frame intended to be expressed and has an ATG start codon, the applicant determined that 
the ATG start codon is upstream of the transcription start site. The transcription start site was 
determined in Stavolone et al. (2003) and Sahoo et al. (2014). Based on all available information, the 
EFSA Panel on Genetically Modified Organisms (GMO Panel) is of the opinion that the likelihood 
that these ORFs are both transcribed and translated in maize 5307 is negligible. 
No significant similarities with known allergens were found with the eCry3.1Ab protein. There was a 
match of eight identical amino acids between the sequence encoding PMI and α-parvalbumin from 
Rana sp. CH2001. This is discussed further in Section 5.1.4.  
Bioinformatic analyses revealed no relevant similarities between the amino acid sequence of PMI and 
known toxic proteins.The applicant identified relevant similarities between the amino acid sequence of 
eCry3.1Ab and parasporins, which might act as cytotoxic proteins on mammalian cells, mainly 
tumoral. The assessment of the toxicity of eCry3.1Ab for humans and animals is discussed in Section 
5.1.2. 
3.1.3. Information on the expression of the insert14 
Levels of the eCry3.1Ab and PMI proteins were analysed by enzyme-linked immunosorbent assay 
(ELISA) in material harvested from replicated field trials across four locations in the USA in 2008. 
Samples analysed included leaf, root and whole plants at four growth stages (whorl, anthesis, maturity 
and senescence), grain samples at maturity and senescence, and pollen samples at anthesis. Data on 
forage was not provided. The mean values and ranges of the eCry3.1Ab and PMI protein levels in 
mature grains (n = 5 per location) are summarised. The mean eCry3.1Ab level across all sites was 
6.19 µg/g dry weight (dw) (SD = 1.87), with a range of 2.37–9.64 µg/g dw. The mean value for PMI 
levels was 2.08 µg/g dw (SD = 0.49) with a range of 1.04–3.82 µg/g dw. 
3.1.4. Inheritance and stability of inserted DNA15 
Stable integration of the insert was confirmed by Southern analysis over four maize 5307 generations 
and the insert followed the Mendelian inheritance pattern of a single locus. This was supported by 
real-time PCR analyses of the ecry3.1Ab and pmi genes. Stability in expression was demonstrated by 
ELISA analyses of eCry3.1Ab and PMI protein levels over four generations. 
3.2. Conclusion 
The molecular characterisation data provided by the applicant establish that the genetically modified 
maize 5307 contains a single insertion consisting of two intact expression cassettes (ecry3.1Ab and 
pmi). No other parts of the plasmid used for transformation are present in the transformed plant. 
Bioinformatic analyses of the ORFs spanning the junction sites within the insert or between the insert 
and genomic DNA did not give rise to safety issues. Sequence identities greater than 35 % with 
allergens were found in putative translation products of ORFs newly created by the genetic 
modification, but the likelihood that these ORFs are both transcribed and translated in maize 5307 is 
negligible. 
                                                     
14
 Dossier: Part I—Section D3; additional information: 12/06/2014. 
15
 Dossier: Part I—Sections D2.3, D5. 
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Bioinformatic analyses revealed relevant similarities between the amino acid sequence of PMI and a 
known allergen. Relevant similarities were also identified between eCry3.1Ab and potential cytotoxic 
proteins. These are further assessed for their relevance for food and feed safety in Section 5. The 
stability of the inserted DNA was confirmed over several generations and a Mendelian inheritance 
pattern was demonstrated. The levels of the eCry3.1Ab and PMI proteins in maize 5307 were obtained 
and reported adequately. 
4. Comparative analysis 
4.1. Evaluation of relevant scientific data 
4.1.1. Choice of comparator 
Field trials for the comparative compositional analysis of maize 5307 and its conventional counterpart 
were carried out at six locations in the USA in 200816, at eight locations in the USA in 200917 and at 
eight locations in Argentina during the 2011/2012 growing season.18 The agronomic and phenotypic 
characteristics of maize 5307 and its conventional counterpart were evaluated at field trials performed 
at five locations in the USA in 200719 and at 12 locations in the USA in 2008.20 The locations selected 
in the USA and in Argentina represent major maize-growing areas. The conventional counterpart in 
these field trials was the non-GM maize NP2171/NP2460, which has a similar genetic background to 
maize 5307, as shown in the pedigree chart. 21  In addition, in 2009, eight commercial non-GM 
varieties22 were grown at eight locations in the USA (Table 1).23 Grain and forage samples were 
harvested for compositional analysis. 
Table 1:  Overview of comparative assessment studies with maize 5307 
Study focus Study details Conventional 
counterpart 
Non-GM maize 
varieties 
Composition of forage/harvested 
grain  
2008, six locations in the 
USA 
1 (NP2171/NP2460) – 
Composition of forage/harvested 
grain 
2009, eight locations in the 
USA 
1 (NP2171/NP2460) – 
Composition of forage/harvested 
grain 
2011/2012, eight locations 
in Argentina24 
1 (NP2171/NP2460) – 
Agronomic and phenotypic 
characteristics 
2007, five locations in the 
USA 
1 (NP2171/NP2460) – 
Agronomic and phenotypic 
characteristics 
2008, 12 locations in the 
USA 
1 (NP2171/NP2460) – 
Establishment of natural 
compositional variation 
2009, eight locations in the 
USA25 
–
26
 817 
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 Stanton (MN), Janesville (WI), New Haven (IN), Shirley (IL), Marshall (MO), Bloomington (IL). 
17
 York (NE), Swanton (OH), Deerfield (MI), Richland (IA), Seymour (IL), York (NE), Kimballton (IA), Elk Horn (IA). 
18
 Tacuari, Berdier, Chacabuco, San Patricio, Carmen de Areco, Arroyo Dulce, Arrecifes, El Crisol. 
19
 Brookings (SD), Waldorf (MN), Corwith (IA), Green Valley (IL), El Paso (IL). 
20
 Brookings (SD), Minnesota Lake (MN), Northfield (MN), Janesville (WI), New Haven (IN), Beaver Crossing (NE), El 
Paso (IL), Bloomington (IL), Shirley (IL), St. Joseph (IL), La Salle (IL), Marshall (MO). 
21
 Dossier: Part I—Section D7.2/Appendix 27, Vol. 1. 
22
 The eight commercial non-GM maize varieties were NK KANSAS, NK SYMBA, X36344, NK THERMO, H-7191, H-
6044, H-6218, H-7540. 
23
 York (NE), Fulton (OH), Lenawee (MI), Richland (IA), Seymour (IL), York (NE), Audobon (IA), Shelby (IA). 
24
 Additional information: 29/01/13, Appendix B5. 
25
 Dossier : Part I—Section D7.2/Appendix 30. 
26
 Neither maize 5307 nor the conventional counterpart was included in these field trials. 
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4.1.2. Agronomic and phenotypic characteristics 
Based on data collected in the USA at five locations in 2007 and at 12 locations in 2008, the applicant 
performed a comparative assessment of 17 phenotypic and agronomic characteristics and two disease 
resistance traits of maize 5307 and its conventional counterpart in 2007 and three additional 
phenotypic and agronomic characteristics (% snapped plants, early root lodging, push test) to the 17 in 
200827. As one location planted in 2007 had a significantly delayed planting date, the data were 
analysed excluding this location. The applicant analysed the data for each season in an across-site 
analysis using an analysis of variance (ANOVA), which identified statistically significant differences 
between maize 5307 and its conventional counterpart for the endpoints ‘heat units to 50 % pollen 
shed’, plant height and grain moisture in 2007 and grain yield in 2008 (Table 2). In all cases the values 
were slightly higher for maize 5307 in comparison to the conventional counterpart. When the field 
trials in 2007 were analysed without the Corwith, IA, location, for which the applicant claimed there 
was a one-month delay in planting compared with the other locations, the parameter ‘plant height’ was 
no longer statistically significantly different. When analysed by a t-test at each site separately, grain 
yield was statistically significantly different at one location in 2008, whereas grain moisture showed 
differences at two locations in each of the 2007 and 2008 growing seasons. The EFSA GMO Panel is 
of the opinion that these differences do not give rise to any food and feed safety concerns. The 
potential impact of the differences on the environment is further discussed in Section 6.1.1.1. 
Table 2:  Statistically significant agronomic and phenotypic differences across locations in field 
trials in 2007 and 2008 (the mean values, together with the standard error of the means, are given).  
 2007 season 2008 season 
Maize 5307 Conventional 
counterpart 
Maize 5307 Conventional 
counterpart 
Grain moisture (%) 17.9 ± 0.2* 16.9 ± 0.2 20.8 ± 0.1 20.3 ± 0.1 
Plant height (cm) 216 ± 1* 210 ± 1 247 ± 2 239 ± 2 
Heat units to 50 % pollen shed 1230 ± 1* 1247± 1 1330 ± 2 1325 ± 2 
Grain yield (kg/ha)** 9380 ± 160 9660 ± 160 9510 ± 150* 8700 ± 150 
* Significance assigned at p < 0.05 level. 
** Data converted to metric units from original results of measurements provided by the applicant in bushels/acre (Bu/A): 
maize 5307 149.5 ± 2.52 Bu/A vs. conventional counterpart 154 ± 2.52 Bu/A in 2007; maize 5307 151.6 ± 2.34 Bu/A vs. 
conventional counterpart 138.6 ± 2.40 Bu/A in 2008. One bushel of maize (US trade unit) corresponds to 56 lbs (25 kg) of 
maize. 
4.1.3. Compositional analysis 
The compounds selected to be analysed in grain and forage followed the OECD recommendations 
(OECD, 2002). In forage, nine parameters (protein, fat, ash, moisture, carbohydrates by calculation, 
acid detergent fibre, neutral detergent fibre, calcium, phosphorus) were analysed and, in grain, 59 
parameters were analysed. 28  Thirteen additional fatty acids were measured but not statistically 
analysed because levels were below the limit of quantification. For each season, the statistical analysis 
                                                     
27
 The following agronomic/phenotypic parameters were measured: number of barren plants, number of plants with dropped 
ears, number of emerged plants, early emergence vigour, early growth vigour, ear height, % grain moisture, % snapped 
plants, early root lodging, plant population at harvest, heat units to 50 % silking, heat units to 50 % pollen shed, late season 
intactness, leaf colour rating, late root lodging, plant height, push test, stalk lodging, test weight, grain yield. 
28
 For the compositional analysis, the following parameters were measured in grain: moisture, protein, fat, ash, 
carbohydrates, acid detergent fibre (ADF), neutral detergent fibre (NDF), total dietary fibre (TDF), starch, calcium, copper, 
iron, magnesium, manganese, phosphorus, potassium, selenium, sodium, zinc, β-carotene, thiamine, riboflavin, niacin, 
pyridoxine, folic acid, α-tocopherol, alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, 
leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, palmitic acid, stearic 
acid, oleic acid, linoleic acid, linolenic acid, arachidic acid, eicosenoic acid, behenic acid, ferulic acid, furfural, inositol, p-
coumaric acid, phytic acid, raffinose, trypsin inhibitor. 
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was a combined-site ANOVA to compare maize 5307 with its conventional counterpart. In the 2008 
field trials, the levels of 16 components (selenium, sodium, furfural and 13 fatty acids) were below the 
limit of quantification in the majority of the analyses and were excluded from the statistical 
comparison, while in the 2009 field trials, the levels of 18 components (selenium, sodium, furfural, 
raffinose and 14 fatty acids) were below the limit of quantification for the majority of the analyses and 
excluded from statistical comparison. Moisture in grain was not statistically analysed due to 
mechanical drying. 
In the case of forage, no compositional differences were observed between maize 5307 and the 
conventional counterpart. The statistical analysis of the compositional data of grain harvested from 
field trials in the USA identified seven statistically significant differences between maize 5307 and the 
conventional counterpart in the 2008 season and 10 in the 2009 season. The level of five of these 
components were different in both seasons (16:0 palmitic acid, 18:0 stearic acid, 18:3 linolenic acid, 
20:1 eicosenoic acid; and β-carotene) (Table 3). The endpoint values for compounds showing 
differences were within the ranges of the non-GM varieties grown in separate field trials in the USA in 
2008 and 2009. 
Table 3:  Statistically significant compositional differences across locations for grain in the field 
trials in 2008 and 2009 (the mean values, together with the standard error of the means, are given).  
 
2008 season 2009 season 2009 season 
Maize 5307 Conventional 
counterpart 
Maize 5307 Conventional 
counterpart 
Non-GM 
varieties range 
Fat 
(% dw) 
4.54 ± 0.067 4.72 ± 0.067 4.26 ± 0.09* 4.58 ± 0.09 2.74–4.89 
Palmitic acid 
(% total FA) 
15.7 ± 0.1* 15.2 ± 0.1 15.2 ± 0.1* 14.9 ± 0.1 10.9–15.9 
Stearic acid  
(% total FA) 
1.74 ± 0.06* 1.81 ± 0.06 1.55 ± 0.02* 1.61 ± 0.02 1.38–2.08 
Linolenic acid 
(% total FA) 
1.60 ± 0.6* 1.50 ± 0.6 1.64 ± 0.01* 1.55 ± 0.01 1.31–2.14 
Arachidic acid 
(% total FA) 
0.392 ± 0.005 0.387 ± 0.005 0.363 ± 0.005* 0.369 ± 0.005 0.338–0.460 
Eicosenoic acid 
(% total FA) 
0.250 ± 0.003* 0.242 ± 0.003 0.249 ± 0.002* 0.243 ± 0.002 0.228–0.333 
Copper 
(mg/kg dw) 
1.52 ± 0.25 1.89 ± 0.25 1.25 ± 0.06* 1.43 ± 0.06 0.97–7.46 
β-Carotene 
(mg/kg dw) 
1.55 ± 0.05* 1.76 ± 0.05 1.51 ± 0.07* 1.68 ± 0.07 0.81–2.59 
α-Tocopherol 
(mg/kg dwW) 
9.3 ± 0.55 9.0 ± 0.55 8.5 ± 0.21* 8.0 ± 0.21 5.8–18.6 
Riboflavin 
(mg/kg dw) 
1.98 ± 0.1 1.98 ± 0.1 2.32 ± 0.07* 2.08 ± 0.07 1.07–3.46 
Pyridoxine 
(mg/kg dw) 
6.92 ± 0.17* 7.37 ± 0.17 5.58 ± 0.13 5.69 ± 0.13 3.30–8.58 
Folic acid 
(mg/kg dw) 
0.40 ± 0.02* 0.38 ± 0.02 0.41 ± 0.02 0.43 ± 0.02 0.17–0.52 
* Significance assigned at p < 0.05 level. 
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Given that PMI is an enzyme involved in carbohydrate metabolism, information on the levels of 
specific compounds linked to the mode of action of PMI in maize 5307 and in its conventional 
counterpart was requested by the EFSA GMO Panel, in order to assess the likelihood of the 
occurrence of unintended effects. In response to this request29, the applicant provided the results of an 
analysis of monosaccharides and disaccharides, sugar alcohols, and their phosphorylated forms, in 
grain derived from maize 5307 and its conventional counterpart grown in an additional field study at 
eight locations in Argentina during the 2011/2012 growing season. Various statistically significant 
increases (of approximately 15%) were observed in the content of several of these carbohydrates 
(mannose 6-phosphate, fructose 6-phosphate, fructose, myo-inositol, sucrose) in maize 5307 compared 
with the conventional counterpart in the combined-site analysis (and in no or a limited number of per-
location statistical analyses for each of these parameters). These were not considered to be attributable 
to the newly expressed PMI enzyme, based, among other factors, on the lack of a plausible 
biochemical mechanism that could account for the presence and direction of the differences observed 
in these components, and on the absence of effects on other carbohydrates. These results are in line 
with previous assessments of GM plants expressing PMI proteins by the EFSA GMO Panel (EFSA, 
2009a; EFSA GMO Panel, 2012). 
The EFSA GMO Panel did not identify a significant difference in the composition of forage and grain 
of maize 5307 that needs further assessment regarding food and feed safety. 
4.2. Conclusion 
Based on the agronomic and phenotypic characteristics of maize 5307 tested under field conditions, 
some differences were noted in maize 5307 compared with its conventional counterpart (i.e. higher 
‘heat units to 50 % pollen shed’, higher grain moisture and higher plant height in 2007 field trials; 
higher grain yield in 2008 field trials). These are addressed in Section 6. 
The EFSA GMO Panel concluded that none of the differences identified in the composition, 
agronomic and phenotypic characteristics of grain and forage obtained from maize 5307 required 
further assessment regarding food and feed safety. 
5. Food/feed safety assessment 
5.1. Evaluation of relevant scientific data 
5.1.1. Effect of processing 
Based on the outcome of the comparative assessment, the effect of processing maize 5307 is not 
expected to be different from that of processing conventional maize. 
5.1.2. Toxicology 
Maize 5307 expresses two new proteins, eCry3.1Ab, conferring insect resistance, and PMI, used as a 
selection marker (see Section 3). 
5.1.2.1. Protein used for safety assessment 
Given the low expression levels of the eCry3.1Ab protein in maize 5307 and the consequent difficulty 
of extracting enough protein from the GM plant, sufficient amounts of the protein were produced in an 
E. coli system (strain DH5α). The structural and functional equivalence of the eCry3.1Ab protein 
derived from E. coli with that expressed in maize 5307 (leaves) was shown by immunoblotting, 
glycosylation analysis and insecticidal activity. Peptide mass mapping analysis was also performed on 
the E. coli- and the maize 5307-expressed proteins. Both eCry3.1Ab proteins react to the same 
antibody upon Western blot analysis and have an expected molecular weight of 73.7 kDa (plant 
derived) and 74.8 kDa (E. coli derived, confirmed by mass spectrometry), respectively. The higher 
                                                     
29
 Additional information: 29/01/2013 
Scientific Opinion on genetically modified maize 5307
 
EFSA Journal 2015;13(5):4083 
 
14 
molecular weight of the E. coli-produced protein is due to seven additional amino acids introduced at 
the N-terminus to facilitate protein purification in the microbial system (histidine-tag). An 
immunologically positive band of 150 kDa was noted for the E. coli-produced protein, probably 
representing a dimer. Both proteins were not glycosylated and showed insecticidal activity. The 
peptide mass mapping analysis identified 76 % and 87 % of the predicted amino acid sequence of 
eCry3.1Ab for the maize 5307- and E. coli-produced proteins, respectively. N-terminal analysis 
confirmed the expected N-terminal amino acid sequence for both proteins. N-terminal acetylation, a 
common modification known for plant-expressed proteins, was observed in the maize 5307-derived 
eCry3.1Ab. 
The EFSA GMO Panel accepts the use of the E. coli-produced eCry3.1Ab protein in the safety studies, 
as it was demonstrated to be equivalent to the plant-produced one. 
The PMI protein expressed in maize 5307 has been assessed in the context of previous applications 
(EFSA GMO Panel, 2012; EFSA, 2013a,b). No safety concerns were identified by the EFSA GMO 
Panel for humans or animals. 
5.1.2.2. Toxicological assessment of the newly expressed proteins 
a) Bioinformatic analyses 
Bioinformatic analyses of the amino acid sequence of the PMI protein revealed no significant 
similarities to proteins known to be toxic to human and animals. 
As indicated in Section 3, the applicant identified significant similarities between the amino acid 
sequence of eCry3.1Ab and parasporin proteins. Parasporins are non-haemolytic and non-insecticidal 
B. thuringiensis (and related bacteria) parasporal proteins that show cytotoxic activity on mammalian 
cells (predominantly tumoral in origin). Cytotoxicity is achieved after proteolytic processing by 
apoptosis or plasma membrane increased permeability (Ohba, 2009). 
b) In vitro degradation studies 
The resistance of the eCry3.1Ab protein to degradation by pepsin was studied in solutions at pH ~ 1.2. 
The integrity of the test protein in samples taken at various time points was analysed by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by protein staining or by 
Western blotting. No intact protein (ca. 74 kDa) was seen after 30 seconds of incubation. Short 
fragments of 4 kDa and 5 kDa in the protein-stained SDS-PAGE gel were observed in samples 
exposed to pepsin for 10 minutes. By Western blot analysis, these fragments were found to be not 
immunologically reactive to a polyclonal antibody against eCry3.1Ab. 
In the application EFSA-GMO-DE-2011-95, the applicant presented an additional in vitro degradation 
study with the PMI protein that confirmed the outcome of a previous in vitro degradation study 
assessed by the EFSA GMO Panel (EFSA GMO Panel, 2012). 
c) Acute toxicity 
In an acute oral toxicity study in Crl:CD-1 (ICR) mice, the eCry3.1Ab protein expressed in E. coli 
induced no adverse effects after administration in a single dose of 1 720 mg/kg body weight. In the 
application EFSA-GMO-DE-2011-95, the applicant presented an additional acute toxicity study with 
the PMI protein that confirmed the outcome of a previous acute oral toxicity study assessed by the 
EFSA GMO Panel (EFSA GMO Panel, 2012). 
The EFSA GMO Panel considers that acute toxicity testing of the newly expressed protein is of little 
value for the risk assessment of the repeated human and animal consumption of food and feed derived 
from GM plants. 
Scientific Opinion on genetically modified maize 5307
 
EFSA Journal 2015;13(5):4083 
 
15 
d) 28-day repeated dose toxicity study 
Following a request by the EFSA GMO Panel, the applicant provided a 28-day repeated dose oral 
toxicity study on eCry3.1Ab in rats.30 This includes the results of two separate experiments, the second 
one being a repetition to collect missed data (liver weight). In the first experiment, five groups of Han 
Wistar Crl: WI (Han) rats (five per gender per group, housed at two and three per cage) were 
administered the eCry3.1Ab protein (produced in E. coli) by gavage at dose levels of 0.36, 3.36 or 
33.6 mg/kg body weight (bw) per day, the vehicle, i.e. water for injection (vehicle control group), or 
bovine serum albumin (BSA, 33.6 mg/kg bw per day; protein control group). During the study, all 
animals were checked daily for mortality and clinical signs. Body weights and feed consumption were 
measured twice weekly, and water consumption was monitored weekly. Ophthalmoscopy was carried 
out before the start of the treatment (all animals) and during week 4 (high-dose group and both control 
groups). Detailed functional examinations (including motor activity) were conducted for all animals 
during week 4. After 28 days of treatment, blood samples were taken for haematology, coagulation 
and clinical chemistry analyses. The animals were necropsied and macroscopically examined; organ 
weights were determined and tissues for histopathology examination were taken in accordance with 
OECD Test Guideline (TG) 407 with the exception of liver weight. Histopathological examination 
was performed on both control groups and the high-dose group. As liver weight was not recorded, the 
study was repeated in accordance with the same overall design, but only liver weights were measured. 
Blood and liver samples were taken but not evaluated. 
The EFSA GMO Panel requested a 28-day toxicity study of sufficient statistical power in rodents to 
support the safety assessment of eCry3.1Ab, particularly considering the lack of history of exposure to 
this protein in humans and animals. However, the study provided by the applicant is not considered 
adequate by the EFSA GMO Panel for both the following reasons: 
• The use of datasets from two separate experiments does not allow the integrated interpretation 
of findings, specifically with reference to potential effects to the liver; 
• The number of animals (five rats per gender per group, two or three per cage) is considered 
insufficient by the EFSA GMO Panel (see EFSA GMO Panel, 2011a); moreover, the dataset 
per treatment and gender is derived from a mixture of independent values (two cages) and 
dependent values (two or three animals per cage). 
Therefore, the EFSA GMO Panel can not conclude on the safety of the newly expressed eCry3.1Ab 
protein. 
5.1.2.3. Toxicological assessment of new constituents other than proteins 
Maize 5307 does not show any compositional difference to its conventional counterpart that would 
require further assessment (see Section 4.1.3). No further food and feed safety assessment of 
components other than newly expressed proteins is required. 
5.1.3. Animal studies with the food/feed derived from GM plants 
A 49-day feeding study using chickens for fattening (both sexes) was provided.31 In this study, 540 
broilers (Heritage, day-old) were randomly allocated into three diet treatment groups with 180 chicks 
per treatment (15 birds of the same sex per pen, and 12 pens per treatment including six with males 
and the other six with females). Maize 5307 was compared with its conventional counterpart and a 
non-GM commercial variety (NCSU 2007 maize). Grain was obtained from plants of maize 5307 and 
its conventional counterpart grown under the same standard local agricultural practices. Before 
formulating the diets, the grain was analysed for proximates, amino acids and mycotoxins. The 
chickens were fed starter (days 1–15), grower (days 16–34) and finisher (days 35–49) diets containing 
52–54%, 56–58 % and 61–63 % of maize, respectively. The diets were adjusted according to the 
                                                     
30
 Additional information: 29/01/13. 
31
 Dossier: Part I—Appendices 38 and 38.1.  
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standards of the Dutch Central Feed Bureau (CVB, 2001, 2002) and the National Research Council 
(NRC, 1994). The feed conversion ratio was calculated as feed consumed by live body weight per pen. 
The concentrations of the newly expressed proteins were determined in the grain and the pelleted diets 
by ELISA and, as expected, a reduction following feed processing was observed.32 Feed and water 
were provided to the birds for ad libitum intake. 
Chickens were observed twice daily for clinical signs; any deaths were recorded. Body weight and 
feed intake were measured on days 1, 16, 35 and 49. At day 50, two birds per pen were taken for post-
mortem carcass evaluation (dressing percentage, weight of thighs, breast, wings, drums and abdominal 
fat). A two-way ANOVA (diet and gender) was applied, using the pen as the experimental unit, for 
performance parameters. A one-way ANOVA was used to analyse the gender-specific carcass 
parameters using individual data. A direct comparison was also made between the group fed the GM 
diet and that fed the conventional counterpart. 
The EFSA GMO Panel could not evaluate the outcome of this study, because of weaknesses in the 
study conduct and reporting. This included (i) discrepancies between the number of animals included 
in the study and that for which results have been reported; (ii) insufficient details given for the 
statistical evaluation and taking feed samples; (iii) inconsistency in the content of eCry3.1Ab and PMI 
proteins in the different diets; and (iv) a marked difference between intended and analysed values of 
dietary protein. 
5.1.4. Allergenicity 
The strategies to assess the potential risk of allergenicity focus on the source of the recombinant 
protein, on the potential of the newly expressed protein to induce sensitisation or to elicit allergic 
reactions in already sensitised persons and on whether the transformation may have altered the 
allergenic properties of the modified plant. 
5.1.4.1. Assessment of allergenicity of the newly expressed proteins33 
A weight-of-evidence approach was followed, taking into account all of the information obtained on 
the newly expressed proteins, as no single piece of information or experimental method yields 
sufficient evidence to predict allergenicity (EFSA, 2006a; Codex Alimentarius, 2009; EFSA GMO 
Panel, 2011a). 
The newly expressed eCry3.1Ab protein is based on fused partial sequences of the mCry3A and 
Cry1Ab proteins, which are both derived from B. thuringiensis, a bacterium not considered to be a 
common allergenic source. Bioinformatic analyses of the amino acid sequence of the eCry3.1Ab 
protein using the criterion of 35 % identity in a window of 80 amino acids revealed no significant 
similarities to known allergens. In addition, the applicant performed analyses searching for matches of 
eight contiguous identical amino acid sequences between this newly expressed protein and known 
allergens, which confirmed the outcome of the above-mentioned bioinformatic analyses showing no 
similarities to known allergens. The study on resistance to degradation by proteolytic enzymes 
presented in the current application has been described in Section 5.1.2.2 and did not give rise to 
safety concerns. 
The toxicity study with the eCry3.1Ab protein presented in this application was considered inadequate 
by the EFSA GMO Panel (see Section 5.1.2.2), and therefore potential adverse effects including those 
on the immune system cannot be assessed. 
With regard to the PMI protein in maize 5307, the gene coding for this newly expressed protein was 
derived from E. coli, which is not considered to be a common allergenic source. Bioinformatic 
analyses of the amino acid sequence of the PMI protein using the criterion of 35 % identity in a 
                                                     
32
 Protein concentrations (µg/kg of dry weight) measured in the maize grain, starter diet, grower diet and finisher diet are, for 
eCry3.1Ab 4.71, 2.13, 0.34 and 0.38; and, for PMI 0.85, 0.67, below limit of detection (LoD), below LoD. 
33
 Dossier: Part I—Section D7.9.1; additional information: 12/06/14, 28/07/14 and 24/03/15. 
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window of 80 amino acids revealed no significant similarities to known allergens. In addition, the 
applicant performed analyses searching for matches of eight contiguous identical amino acid 
sequences between this newly expressed protein and known allergens. An identical eight-amino-acid-
long sequence match between the PMI protein and a frog allergen (i.e. α-parvalbumin from Rana sp. 
CH2001) was reported. This identical match in PMI was previously assessed by the EFSA GMO Panel 
and no safety concerns were identified (EFSA GMO Panel, 2012). The data assessed included an 
immunoblotting analysis provided by the applicant where serum from the same allergic individual 
reported in the literature to react to the frog leg allergen in Rana sp. CH2001 did not bind to PMI. The 
study on resistance to degradation by proteolytic enzymes presented in the current application 
confirmed the outcome of a previous in vitro degradation study assessed by the EFSA GMO Panel 
(EFSA GMO Panel, 2012; see also Section 5.1.2.2). There is no information available on the structure 
or function of the newly expressed PMI protein that would suggest an adjuvant effect resulting in or 
increasing an eventual immunoglobulin (Ig) E response to a bystander protein. 
The EFSA GMO Panel has previously evaluated the safety of the PMI protein in the context of other 
applications and no concerns on allergenicity were identified (e.g. EFSA GMO Panel, 2012; EFSA 
2013a,b). 
In the context of this application, the EFSA GMO Panel considered that there are no indications that 
the newly expressed PMI protein in maize 5307 may be allergenic. 
5.1.4.2. Assessment of allergenicity of the whole GM plant34 
To date, maize has not been considered to be a common allergenic food 35  (OECD, 2002), and 
therefore the EFSA GMO Panel did not request experimental data to analyse the allergen repertoire of 
GM maize. The EFSA GMO Panel regularly reviews the available publications on food allergy to 
maize (e.g. EFSA, 2013b). 
For the allergenicity assessment of the whole GM plant in maize 5307, the EFSA GMO Panel took 
into account the data from the molecular characterisation, the comparative analysis and the assessment 
of the newly expressed proteins. Considering that the safety assessment of the eCry3.1Ab protein 
could not be completed (see Sections 5.1.2.2 and 5.1.4.1), no conclusions could be reached regarding 
the overall allergenicity of maize 5307. 
5.1.5. Nutritional assessment of GM food/feed 
The intended trait of maize 5307 is insect resistance, with no intention of altering the nutritional 
parameters. Comparison of the nutrients and anti-nutrients of maize 5307 with its conventional 
counterpart did not identify differences that would require further safety assessment (see Section 
4.1.3). From these data, an impact on the nutritional value of maize 5307-derived food and feed is not 
expected. 
5.1.6. Post-market monitoring of GM food/feed 
As the EFSA GMO Panel could not complete the safety assessment of maize 5307, the EFSA GMO 
Panel is currently not in a position to formulate any recommendation for a potential post-market 
monitoring of maize 5307. 
5.2. Conclusion 
The EFSA GMO Panel could not complete the food and feed safety assessment of maize 5307 due to 
the lack of an appropriate assessment of the eCry3.1Ab protein. 
                                                     
34
 Dossier: Part I—Section D7.9.2. 
35
 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to 
Directive 2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 
27.11.2007, p. 11–14. 
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6. Environmental risk assessment and monitoring plan 
6.1. Evaluation of relevant scientific data 
Considering the scope of application EFSA-GMO-DE-2011-95, the environmental risk assessment 
(ERA) is mainly concerned with (i) exposure of bacteria to recombinant DNA in the gastrointestinal 
tract of animals fed GM material and bacteria present in environments exposed to faecal material, and 
(ii) accidental release into the environment of viable grains of maize 5307 during transport and 
processing. 
6.1.1. Environmental risk assessment 
6.1.1.1. Potential unintended effects on plant fitness due to the genetic modification36 
Maize is highly domesticated and generally unable to survive in the environment without management 
intervention. Maize plants are not winter hardy in many regions of Europe; they have lost their ability 
to release seeds from the cob and they do not occur outside cultivated land or disturbed habitats in the 
agricultural landscapes of Europe, despite cultivation for many years. In cultivation, maize volunteers 
may arise under some environmental conditions (mild winters). Observations made on cobs, cob 
fragments or isolated grains shed in the field during harvesting indicated that grain may survive and 
overwinter in some regions, resulting in volunteers in subsequent crops. The occurrence of maize 
volunteers has been reported in Spain and other European regions (e.g. Gruber et al., 2008). However, 
maize volunteers have been shown to grow weakly and flower asynchronously with the maize crop 
(Palaudelmàs et al., 2009). 
As mentioned in Sections 4.1.1 and 4.1.2, field trials were carried out in the USA in 2007 and 2008 to 
assess the agronomic and phenotypic performance37 of maize 5307 in comparison with its conventional 
counterpart. Several agronomic and phenotypic characteristics38 were measured. Considering the scope 
of application EFSA-GMO-DE-2011-95, special attention is paid to those agronomic characteristics that 
may affect the survival, establishment and fitness of maize 5307 grains that could be accidentally 
released into the environment, e.g. early and final stand count, plant vigour, grain test weight and yield. 
In the across-site analysis of 2007 field trial data, maize 5307 had a higher percentage grain moisture, 
higher heat units to 50 % pollen shed and a higher plant height than its conventional counterpart. In 
the across-site analysis of 2008 field trial data, grain yield for maize 5307 was significantly higher 
than for its conventional counterpart (see Table 2). Although the 2007 field trial data show some 
statistically significant differences in some parameters (i.e. grain moisture, heat units to 50 % pollen 
shed, plant height), the EFSA GMO Panel recognises that these differences are small in magnitude. 
The EFSA GMO Panel is thus of the opinion that they do not give rise to any environmental safety 
concerns. Moreover, the 2007 field trial data indicate no difference in grain yield for maize 5307 and 
its conventional counterpart. 
The EFSA GMO Panel acknowledges the difference in grain yield between maize 5307 and its 
conventional counterpart in the 2008 field trial. The EFSA GMO Panel also notes that maize 5307 and 
its conventional counterpart did not differ for other agronomic parameters that are likely to indicate a 
change in fitness potential of the GM maize, such as, for example, number of emerged plants per plot 
prior to thinning, early growth vigour and number of plants at harvest. 
Therefore, considering the scope of application EFSA-GMO-DE-2011-95 and the poor ability of 
maize to survive outside cultivated areas in case of accidental spillage, the EFSA GMO Panel 
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38
 The following agronomic/phenotypic parameters were measured: number of barren plants, number of plants with dropped 
ears, number of emerged plants, early emergence vigour, early growth vigour, ear height, % grain moisture, % snapped 
plants, early root lodging, plant population at harvest, heat units to 50 % silking, heat units to 50 % pollen shed, late season 
intactness, leaf colour rating, late root lodging, plant height, push test, stalk lodging, test weight, grain yield. 
Scientific Opinion on genetically modified maize 5307
 
EFSA Journal 2015;13(5):4083 
 
19 
concludes that the aforementioned differences do not indicate a change in the overall fitness, 
invasiveness or weediness of maize 5307 that would raise any relevant environmental safety concerns. 
In addition to the data presented by the applicant, the EFSA GMO Panel is not aware of any scientific 
report of increased spread and establishment of maize 5307 or maize with comparable properties or of 
any change in survival capacity, including overwintering. 
Insect resistance against certain coleopteran target pests provides a potential agronomic advantage in 
cultivation conditions involving infestation by the target pests. However, survival of maize plants 
outside cultivation or other areas is limited mainly by a combination of low competitiveness, the 
absence of a dormancy phase and susceptibility to plant pathogens, herbivores and cold climatic 
conditions. Based on the inserted traits, the EFSA GMO Panel considers that these general 
characteristics are unchanged in maize 5307. Therefore, the EFSA GMO Panel is of the opinion that 
the likelihood of unintended environmental effects due to the accidental release into the environment 
of viable grains from maize 5307 will not differ from that of conventional maize varieties. 
6.1.1.2. Potential for gene transfer39 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either horizontal gene transfer of DNA or vertical gene flow via seed spillage and cross-pollination. 
(a) Plant-to-bacteria gene transfer 
Genomic DNA is a component of many food and feed products derived from maize. It is well 
documented that DNA present in food and feed becomes substantially degraded during processing and 
digestion in the human or animal gastrointestinal tract. However, a low level of exposure of fragments 
of ingested DNA, including the recombinant fraction of such DNA, to microorganisms, especially 
bacteria, in the digestive tract of humans, domesticated animals and other environments exposed to the 
GM plant or plant material is expected. 
Current scientific knowledge of recombination processes in bacteria suggests that horizontal transfer 
of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as plants 
to bacteria) is not likely to occur at detectable frequencies under natural conditions (see EFSA, 
2009a,b for further details). 
Successful horizontal transfer would require stable insertion of the transgene sequences into a bacterial 
genome and a selective advantage to be conferred on the transformed host. The only mechanism 
known to facilitate horizontal transfer of non-mobile, chromosomal DNA fragments to bacterial 
genomes is homologous recombination. In the case of sequence similarity between the transgenic 
DNA and the natural variants of the gene in bacteria, recombination could result in gene replacement 
in bacteria. In the case of two pairs of sequences with sufficient length of identity and correct 
orientation, recombination could facilitate the transfer of insert sequences to bacterial recipients by 
double homologous recombination. 
Maize 5307 contains several genetic elements of bacterial origin. These are the coding sequences of 
the pmi gene from E. coli and of ecry3.1Ab, a synthetic gene that is based on the cry1Ab and the 
modified cry3A (mcry3A) genes derived from B. thuringiensis and consists of a fusion between the 5′ 
end of the mcry3A domain (459 bp) and the 3′ end of the cry1Ab domain (172 bp). Furthermore, maize 
5307 also contains two nos-terminator sequences originating from the Ti plasmid of Agrobacterium 
tumefaciens. Whereas E. coli is considered to be prevalent in the main receiving environment, i.e. the 
gastrointestinal (GI) tract of humans or animals, B. thuringiensis is not considered to be an inhabitant 
of the GI tract of humans and animals, and, thus, the presence of strains carrying cry3A or cry1Ab 
genes is expected to be very low. B. thuringiensis strains can be isolated from soil and are frequently 
found in material from the guts of various insects (Jensen et al., 2003). Equally, A. tumefaciens, or its 
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close relatives from the genus Rhizobium, is not expected to be prevalent in the GI tract. However, 
occurrence of the recombinant genes outside the immediate receiving environment, in habitats where 
E. coli may also occur and B. thuringiensis or A. tumefaciens is more abundant, cannot be ruled out 
(Hart et al., 2009) and is therefore also taken into account for assessing the risks associated with 
horizontal gene transfer. 
On a theoretical basis (i.e. without any study providing experimental evidence for the occurrence of 
horizontal gene transfer in the case of GM food and feed derived from maize 5307 or any other GM 
plant), it can be assumed that, as an extremely rare event, homologous recombination may occur in the 
environment between nucleotide sequences of the recombinant ecry3.1Ab and pmi genes and their 
natural variants, as they may occur for ecry3.1Ab in certain B. thuringiensis strains and pmi in E. coli 
or other bacteria, with pmi genes providing sufficient sequence identity. 
The nos-terminator sequences present in maize 5307, each with a length of 200 bp, may facilitate 
double homologous recombination with corresponding nos genes on Ti plasmids of environmental A. 
tumefaciens strains. Theoretically, such a recombination could result in the acquisition of the pmi gene 
on natural Ti plasmids and a possible decrease in the expression potential of the nos gene due to the 
replacement of part of its termination sequence by the pmi gene. Due to the conjugative gene transfer 
system encoded by the Ti plasmid, i.e. the tra-system, the potential for transfer of the pmi gene to 
other bacteria that can serve as recipients of the Ti plasmid could be enhanced (Zatyka and Thomas, 
1998). Such bacteria would thereby gain the genetic potential to utilise mannose as a carbon and 
energy source. As the nos sequence-flanked pmi gene present in maize 5307 is contained within the 
vir-system, environmental A. tumefaciens with a recombinant Ti plasmid would also gain the capacity 
to transfer the pmi gene to plant cells where it could be integrated into the plant genome together with 
the genes converting the plant cells to crown gall tumour cells. The crown gall tumour cells would 
thereby receive the genetic potential to produce the enzyme phosphomannose isomerase and, upon 
expression, gain the capacity to convert mannose 6-phosphate to fructose 6-phosphate, which could 
then be metabolised though gluconeogenesis (Zhengquan He et al., 2004), whereas non-transformed 
cells cannot metabolise mannose 6-phosphate. 
In addition to homology-based recombination processes, illegitimate recombination that does not 
require the presence of DNA similarity between the recombining DNA molecules is theoretically 
possible. However, the transformation rates for illegitimate recombination were considered to be 1010-
fold lower than for homologous recombination (Hülter and Wackernagel, 2008; EFSA, 2009b). 
Illegitimate recombination events have not been detected in studies that have exposed bacteria to high 
concentrations of GM plant DNA (EFSA, 2009b). Thus, this process, in comparison to homologous 
recombination, is not considered to contribute significantly to horizontal gene transfer events. In 
comparison to the above-described homology-facilitated recombination processes, the contribution of 
illegitimate recombination is extremely low. 
Both protein-encoding genes from bacteria are regulated in maize 5307 by promoters optimised for 
expression in plants: the ecry3.1Ab gene of maize 5307 by a eukaryotic plant promoter (derived from 
the Arabidopsis thaliana RbcS4) and the pmi gene by the promoter of the Zea mays polyubiquitin 
gene. The expression of the prRBCS4–cry3.1Ab and ZmUbiInt–manA constructs in bacteria is 
unknown, but generally the expression level of eukaryotic promoters in bacteria is inefficient (Warren 
et al., 2008). Therefore, the acquisition of the pmi gene by bacterial recipients, including those that 
would receive a recombinant Ti plasmid (see above) is unlikely to confer a high level of expression of 
the enzyme phosphomannose isomerase. Plant cells transformed with the Ti plasmid containing the 
pmi gene could, however, considering the plant-derived promoter, gain the capacity to utilise mannose 
for growth. However, the replacement of part of the nos terminator sequence by the pmi gene would 
result in decreased expression of nopaline synthase, which would decrease the utilisation of nopaline 
by the plant cells. 
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The following potential environmental implications are considered: 
(1) Substitutive recombination between partial sequences of the synthetic ecry3.1Ab gene or the 
pmi gene with natural variants, as they may occur in habitats receiving DNA of maize 5307 
and bacteria would only replace natural variants (substitutive recombination) and are therefore 
unlikely to provide any new property connected to a selective advantage for the recipient 
organisms (EFSA, 2009b). 
(2) Bacterial recipients of Ti plasmids with the pmi gene could gain the genetic potential to utilise 
mannose as a carbon and energy source, but due to the plant-specific promoter, expression of 
this gene is expected to be low. Furthermore, phosphomannose isomerases are expected to 
occur in many different environmental bacteria and fungi and, thus, the trait is expected to be 
common in receiving environments. Therefore, the ecological implications of bacterial 
recipients with a poorly expressed pmi gene on Ti plasmids are expected to be very low. 
(3) Plant tumour cells infected by crown gall disease via the vir-system of A. tumefaciens Ti 
plasmids, including the pmi gene, would gain a selective advantage to utilise mannose as a 
carbon source, which would coincide with decreased utilisation of nopaline. The major carbon 
source of plant cells originates from photosynthetically assimilated carbon that is transported 
via the phloem, mainly in the molecular form of sucrose and amino acids but not mannose, to 
the plant cells. Thus, a selective advantage of utilising mannose is not apparent. Furthermore, 
the potential utilisation of mannose by the plants would be accompanied by a loss of capacity 
to utilise nopaline. Therefore, the risk associated with an additional pmi gene in the nos 
terminator in crown gall tumour cells is regarded as being very low. 
The EFSA GMO Panel concludes that the ecry3.1Ab and pmi genes from maize 5307 may, on a 
theoretical basis, be transferred by homologous recombination to environmental strains of B. 
thuringiensis or E. coli, where they could replace, in the case of the pmi gene, natural variants of the 
gene or, in the case of the ecry3.1Ab gene, partial regions of the cry1Ab or cry3A genes. As B. 
thuringiensis is not considered to be a member of the gut microbial community, its exposure to 
recombinant DNA of maize 5307 is considered to be very low, while an abundance of pmi gene 
variants in E. coli or related enterobacteriaceae can be expected. Due to the occurrence of natural 
variants of the cry and pmi genes in the environment, low-level gene replacement by horizontal gene 
transfer is not regarded as conferring a novel selective advantage. Similarly, the substitutive 
recombination of nos sequences, as present in DNA of maize 5307, with nos sequences present in 
strains of A. tumefaciens, which are not expected to be prevalent in the main receiving environment, 
would not confer a new trait. On a theoretical basis, horizontal gene transfer events may result in A. 
tumefaciens strains with Ti plasmids carrying the pmi gene in the nos terminator sequence and, thus, 
allow further transfer of the pmi gene via the tra-system to other bacteria or via the vir-system to 
crown gall cells in plants. While these transfers potentially may confer a new trait to bacterial or plant 
recipients, due to conferring the capacity to utilise mannose, the EFSA GMO Panel did not consider 
this altered metabolic potential to be a selective advantage and, thus, of concern due to (i) the wide 
abundance of natural variants of phosphomannose isomerases in environmental microbial 
communities, and (ii) the fact that plant tumour cells do not receive significant amounts of mannose 
under natural conditions. 
Considering the scope of application EFSA-GMO-DE-2011-95, the EFSA GMO Panel concluded that 
the unlikely but theoretically possible horizontal gene transfer of recombinant genes from maize 5307 
to bacteria does not raise any environmental safety concerns. 
(b) Plant-to-plant gene transfer 
Considering the scope of application EFSA-GMO-DE-2011-95 and the physical characteristics of 
maize grain, possible pathways of gene dispersal are grain spillage and the dispersal of pollen from 
occasional feral GM maize plants originating from accidental grain spillage during transport and 
processing. 
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The extent of cross-pollination with other maize varieties will depend mainly on the scale of 
accidental release during transport and processing, and on the successful establishment and subsequent 
flowering of this GM maize plant. For maize, any vertical gene transfer is limited to other Zea mays 
plants, as populations of sexually compatible wild relatives of maize are not known in Europe 
(Eastham and Sweet, 2002; OECD, 2003). 
The flowering of occasional feral GM maize plants originating from accidental release occurring 
during transport and processing is unlikely to disperse significant amounts of GM maize pollen to 
other maize plants. Field observations performed on maize volunteers after GM maize cultivation in 
Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-
pollinated neighbouring plants only at low levels (Palaudelmàs et al., 2009). 
Although the occurrence of some GM maize plants outside cropped areas has been reported in Korea 
due to grain spillage during import, transport, storage, handling and processing (Kim et al., 2006; Lee 
et al., 2009; Park et al., 2010), survival of maize plants outside cultivation in Europe is mainly limited 
by a combination of low competitiveness, the absence of a dormancy phase and susceptibility to plant 
pathogens, herbivores and frost. As these general characteristics are unchanged in maize 5307, insect 
resistance is not likely to provide a selective advantage outside cultivation or under infestation by 
target pests in Europe. Therefore, as for any other maize varieties, these GM maize plants would only 
survive in subsequent seasons in warmer regions of Europe and are not likely to establish feral 
populations under European environmental conditions. 
The EFSA GMO Panel takes into account the fact that this application does not include cultivation of 
maize 5307 within the EU, so that the likelihood of cross-pollination between cultivated maize and the 
occasional feral maize plants resulting from grain spillage is considered extremely low. 
In conclusion, as maize 5307 has no altered survival, multiplication or dissemination characteristics, 
except under infestation by target pests, the EFSA GMO Panel is of the opinion that the likelihood of 
unintended environmental effects as a consequence of the spread of genes, resulting from imports of 
this maize in Europe, will not differ from that of conventional maize varieties. 
6.1.1.3. Interactions of the genetically modified plant with target organisms40 
Considering the scope of application EFSA-GMO-DE-2011-95, and the low level of exposure to the 
environment, potential interactions of the GM plant with target organisms were not considered a 
relevant issue by the EFSA GMO Panel. 
6.1.1.4. Interactions of the genetically modified plant with non-target organisms41 
Considering the scope of application EFSA-GMO-DE-2011-95, and the low level of exposure to the 
environment, potential interactions of the GM plant with non-target organisms were not considered a 
relevant issue by the EFSA GMO Panel. 
However, the EFSA GMO Panel evaluated whether the eCry3.1Ab protein might potentially affect 
non-target organisms by entering the environment through faecal material of animals fed this GM 
maize. Cry proteins are degraded by enzymatic activity in the gastrointestinal tract, meaning that only 
a very low amount of these proteins would remain intact to pass out in faeces. This has been 
demonstrated for Cry1Ab (Einspanier et al., 2004; Lutz et al., 2005, 2006; Wiedemann et al., 2006; 
Guertler et al., 2008; Paul et al., 2010) and Cry1Ab/Ac fusion protein (Xu et al., 2009). There would, 
subsequently, be further degradation of the protein in the faecal material due to microbiological 
proteolytic activity. In addition, there would be further degradation of Cry proteins in soil reducing the 
possibility for exposure of potentially sensitive non-target organisms. While Cry proteins may bind to 
clay minerals and humic substances in soil, thereby reducing their availability to microorganisms for 
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degradation, there are no indications of persistence and accumulation of Cry proteins from GM crops 
in soil (reviewed by Icoz and Stotzky, 2008). 
The EFSA GMO Panel is not aware of evidence of released Cry proteins from GM plants causing 
significant negative effects on soil micro- or macroorganisms. 
Considering the scope of application EFSA-GMO-DE-2011-95, it can be concluded that the exposure 
of potentially sensitive non-target organisms to the eCry3.1Ab protein is likely to be very low and of 
no biological relevance. 
6.1.1.5. Interactions with the abiotic environment and biochemical cycles42 
Considering the scope of application EFSA-GMO-DE-2011-95, and the low level of exposure to the 
environment, potential interactions with the abiotic environment and biogeochemical cycles were not 
considered a relevant issue by the EFSA GMO Panel. 
6.1.2. Post-market environmental monitoring43 
The objectives of a post-market environmental monitoring (PMEM) plan according to Annex VII of 
Directive 2001/18/EC are: (i) to confirm that any assumption regarding the occurrence and impact of 
potential adverse effects of the GMO, or its use, in the environmental risk assessment are correct; and 
(ii) to identify the occurrence of adverse effects of the GMO, or its use, on human health or the 
environment that were not anticipated in the ERA. 
Monitoring is also related to risk management, and thus a final adoption of the PMEM plan falls 
outside the mandate of the EFSA GMO Panel. However, the EFSA GMO Panel gives its opinion on 
the scientific quality of the PMEM plan provided by the applicant (EFSA, 2006b; EFSA GMO Panel,  
2011b). 
The PMEM plan proposed by the applicant includes (i) the description of an approach involving 
operators (federations involved in maize import and processing), reporting to applicants, via a 
centralised system, any observed adverse effect(s) of GMOs on human health and the environment; 
(ii) a coordinating system established by EuropaBio for the collection of the information recorded by 
the various operators; and (iii) the use of networks of existing surveillance systems (Lecoq et al., 2007; 
Windels et al., 2008). The applicant proposes submitting a PMEM report on an annual basis. 
The EFSA GMO Panel is of the opinion that the PMEM plan provided by the applicant, including the 
reporting intervals, is in line with the scope of application EFSA-GMO-DE-2011-95, as the ERA did 
not cover cultivation and identified no potential adverse environmental effects. No case-specific 
monitoring is necessary. The EFSA GMO Panel agrees with the reporting intervals proposed by the 
applicant in its PMEM plan. 
6.2. Conclusion 
There are no indications of an increased likelihood of establishment and spread of feral maize plants. 
Considering the scope of application EFSA-GMO-DE-2011-95, interactions with the biotic and abiotic 
environment were not considered to be a relevant issue. The EFSA GMO Panel also concludes that, 
considering the scope of application EFSA-GMO-DE-2011-95, the unlikely but theoretically possible 
horizontal gene transfer of recombinant genes from maize 5307 to bacteria does not give rise to any 
environmental safety concerns. The PMEM plan and reporting intervals are in line with the scope of 
application EFSA-GMO-DE-2011-95. 
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OVERALL CONCLUSIONS AND RECOMMENDATIONS 
The EFSA GMO Panel was asked to carry out a scientific risk assessment of maize 5307 for import, 
processing, and food and feed uses in accordance with Regulation (EC) No 1829/2003. 
The molecular characterisation data provided for maize 5307 raised issues to be further assessed for 
food and feed safety. The EFSA GMO Panel identified relevant similarities between the amino acid 
sequence of PMI and a known allergen, and between the amino acid sequence of eCry3.1Ab and a 
potential toxin. 
Differences observed in the agronomic and phenotypic characteristics of maize 1507 tested under field 
conditions and compared with its conventional counterpart did not give rise to any food and feed or 
environmental safety concerns. No differences requiring further assessment with regard to safety by 
the EFSA GMO Panel were identified from analyses of compositional data of forage or grains 
obtained from maize 5307 and its conventional counterpart. 
No safety concerns were identified regarding the potential toxicity and allergenicity of the newly 
expressed protein PMI. The 28-day rat oral toxicity study on eCry3.1Ab, provided to support the 
safety assessment of this newly expressed protein, was not considered adequate by the EFSA GMO 
Panel. Therefore, the EFSA GMO Panel cannot conclude on the safety of the eCry3.1Ab protein. The 
EFSA GMO Panel could not evaluate the outcome of a feeding study in broilers with maize 5307 
because of study weaknesses. 
The application GMO-DE-2011-95 concerns food and feed uses and import and processing. Therefore, 
there is no requirement for scientific information on possible environmental effects associated with the 
cultivation of maize 5307. There are no indications of an increased likelihood of establishment and 
spread of feral maize plants. Considering the scope of application EFSA-GMO-DE-2011-95, 
interactions with the biotic and abiotic environment were not considered to be a relevant issue. The 
EFSA GMO Panel also concludes that, considering the scope of application EFSA-GMO-DE-2011-
95, the unlikely but theoretically possible horizontal gene transfer of recombinant genes from maize 
5307 to bacteria does not give rise to any environmental safety concerns. The PMEM plan and 
reporting intervals are in line with the scope of application EFSA-GMO-DE-2011-95. 
In conclusion, the EFSA GMO Panel could not complete the food and feed safety assessment of maize 
5307 due to the lack of an appropriate assessment of the eCry3.1Ab protein. However, the EFSA 
GMO Panel concludes that maize 5307 is unlikely to have any adverse effect on the environment in 
the context of the scope of application EFSA-GMO-DE-2011-95. 
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DOCUMENTATION PROVIDED TO EFSA 
1. Letter from the Competent Authority of Germany, received on 7 April 2011, concerning a 
request for placing on the market of genetically modified maize 5307, submitted by Syngenta 
Crop Protection AG in accordance with Regulation (EC) No 1829/2003. 
2. Acknowledgement letter, dated 27 April 2011, from EFSA to the German Competent Authority. 
3. Letter from EFSA to applicant, dated 13 May 2011, requesting additional information under 
completeness check. 
4. Letter from applicant to EFSA, received on 31 May 2011, providing additional information 
under completeness check. 
5. Letter from EFSA to applicant, dated 21 June 2011, delivering the ‘Statement of Validity’ of 
application for the authorisation of genetically modified maize 5307, application EFSA-GMO-
DE-2011-95, submitted by Syngenta Crop Protection AG in accordance with Regulation (EC) 
No 1829/2003. 
6. Letter from EFSA to applicant, dated 15 July 2011, requesting additional information and 
stopping the clock on behalf of the DG JRC/EURL-GMFF. 
7. Letter from applicant to EFSA, received on 2 August 2011, providing a timeline for submission 
of responses. 
8. Letter from EFSA to applicant, dated 13 September 2011, requesting additional information and 
maintaining the clock stopped. 
9. Letter from applicant to EFSA, received on 3 October 2011, providing additional information. 
10. Letter from EFSA to applicant, dated 14 October 2011, requesting additional information and 
maintaining the clock stopped. 
11. Letter from applicant to EFSA, received on 7 December 2011, providing a timeline for 
submission of responses. 
12. Letter from DG JRC/EURL-GMFF to EFSA, received on 14 September 2012, asking EFSA to 
re-start the clock. 
13. Letter from EFSA to applicant, dated 15 November 2012, requesting additional information and 
maintaining the clock stopped on behalf of the DG JRC/EURL-GMFF. 
14. Letter from applicant to EFSA, received on 29 November 2012, requesting extension of the 
timeline for submission of responses. 
15. Letter from applicant to EFSA, received on 29 January 2013, providing additional information. 
16. Letter from EFSA to applicant, dated 25 June 2013, requesting additional information and 
maintaining the clock stopped. 
17. Letter from applicant to EFSA, received on 8 August 2013, providing additional information. 
18. Letter from EFSA to applicant, dated 17 October 2013, re-starting the clock. 
19. Letter from EFSA to applicant, dated 17 January 2014, re-starting the clock for DG JRC/EURL-
GMFF and corrigendum of EFSA letter to applicant, dated 17 October 2013. 
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20. Letter from EFSA to applicant, dated 27 May 2014, requesting additional information and 
stopping the clock. 
21. Letter from applicant to EFSA, received on 12 June 2014, providing the additional information 
requested. 
22. Letter from EFSA to applicant, dated 2 July 2014, re-starting the clock. 
23. Letter from applicant to EFSA, received on 28 July 2014, submitting additional information 
spontaneously. 
24. Letter from EFSA to applicant, dated 9 September 2014, requesting additional information and 
stopping the clock. 
25. Letter from applicant to EFSA, received on 18 September 2014, providing additional 
information. 
26. Letter from EFSA to applicant, dated 29 October 2014, requesting additional information and 
maintaining the clock stopped. 
27. Letter from applicant to EFSA, received on 11 December 2014, providing additional 
information. 
28. Letter from EFSA to applicant, dated 16 February 2015, requesting additional information and 
maintaining the clock stopped. 
29. Letter from EFSA to applicant, dated 27 February 2015, requesting additional information and 
maintaining the clock stopped 
30. Letter from applicant to EFSA, received on 24 March 2015, providing additional information. 
31. Letter from EFSA to applicant, dated 14 April 2015, re-starting the clock. 
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